Gyros Establishes Dedicated Office in Japan
News Sep 23, 2016
Gyros Protein Technologies AB has announced that it has established a dedicated office in Tokyo, Japan and has established Gyros Japan KK. The dedicated Japan team provides sales, applications and service support in Japan for the Company’s Gyros’ immunoassay business.
Gyros Japan KK replaces support previously provided under the distribution agreement in Japan with GE Healthcare for Gyros Protein Technologies’ nanoliter-scale immunoassay platform business (Gyrolab xP workstation, Gyrolab xPlore, related reagents, consumables and service).
GE Healthcare will continue providing support for sales, technical support and maintenance service until the end of December 2016. Gyros Japan KK will take over full responsibility for the region from January 2017, ensuring a smooth transition for customers.
Peter Luk, Vice President Asia-Pacific, Gyros Protein Technologies, said: “We are delighted to
announce the opening of the Japan office, and would like to thank GE Healthcare for their continued support during this transition period. This marks an important development for Gyros Protein Technologies and demonstrates the company’s commitment to the Asia-Pacific region, which has seen significant growth in the biotherapeutic discovery, development and manufacturing markets in recent years.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE